Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: PR Web
BOSTON (PRWEB) October 21, 2019 The Massachusetts General Hospital (MGH) Down Syndrome Program was the first approved research site in the first clinical trial in the Down Syndrome – Clinical Trials Network (DS-CTN). MGH is enrolling adults with Down Syndrome over the age of 25 in the Longitudinal Investigation for Enhancing Down Syndrome Research Study (LIFE-DSR) to better understand the health issues facing people with Down syndrome as they age, particularly their risk for Alzheimer's disease and dementia. The Down Syndrome Program is one of two MGH sites participating in the LIFE DSR Study with the Department of Neurology expected to begin their recruitment later this year. "In spite of recent advances in medical care, adults with Down syndrome continue to face very significant challenges including a markedly increased risk of Alzheimer disease," said Brian Skotko, MD, MPP, the Emma Campbell Endowed Chair on Down Syndrome at Massachusetts General Hospital (MGH) and director of the
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeGlobeNewswire
- Down's Syndrome Market to Exhibit Growth at a CAGR of 3.81% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- AC Immune's stock jumps after Parkinson's therapy shows signs of benefit [Yahoo! Finance]Yahoo! Finance
- AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
ACIU
Earnings
- 11/5/24 - Beat
ACIU
Sec Filings
- 12/18/24 - Form 6-K
- 12/13/24 - Form SC
- 12/10/24 - Form 6-K
- ACIU's page on the SEC website